Although the endocannabinoid system has been intensely studied, there are still few drugs approved or in development that interact with it.
Yuval Cohen, Ph.D., CEO of Corbus Pharmaceuticals Holdings, spoke with Med Ad News about what the endocannabinoid system is, Corbus’ pipeline of drugs, and why he thinks there will be a flood of drugs targeting the endocannabinoid system.
The medical cannabis market in the United States, even with all of its restrictions, continues to be a fertile area not only for dispensaries, but pharma companies developing cannabis-derived drugs; and proponents say further growth can be generated by educating physicians about medical cannabis.